Risk Reward Update

Research evidence excerpt

Not for redistribution without written consent of Morgan Stanley

M

Update

August 7, 2026 08:31 PM GMT

Morgan Stanley & Co. LLC

10X Genomics Inc | North America

Kallum L Titchmarsh

Equity Analyst

Risk Reward Update

10X Genomics Inc (TXG.O, TXG US)

What’s Changed

10X Genomics Inc (TXG.O)

From

To

Bull Case

$52.00

$53.00

Updated Components

EPS

Life Science Tools & Diagnostics | United States of

America

Stock Rating

Industry View

Price target

Shr price, close (Aug 6, 2026)

52-Week Range

Equal-weight

In-Line

$40.00

$45.60

$50.34-11.16

Risk Reward for 10X Genomics Inc (TXG.O) has been updated

Fiscal Year Ending

12/25 12/26e 12/27e 12/28e

Reason for change

EPS ($)**

Prior EPS ($)**

(0.34)

We update our TXG model following Q2 2026 earnings results.

(0.64)

(0.63)

(0.43)

(0.44)

(0.12)

(0.16)

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare

framework

** = Based on consensus methodology

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with

companies covered in Morgan Stanley Research. As a result,

investors should be aware that the firm may have a conflict of

interest that could affect the objectivity of Morgan Stanley

Research. Investors should consider Morgan Stanley

Research as only a single factor in making their investment

decision.